13:05 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

AIR001: Ph I/II started

Mast Therapeutics said the University of Pittsburgh , (Pittsburgh, Pa.) began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate AIR001. Mast will provide the compound and nebulizers for the study. Mast Therapeutics Inc. (NYSE-M:MSTX),...
19:52 , Mar 15, 2017 |  BC Week In Review  |  Company News

Mast, University of Pittsburgh deal

Mast's Aires Pharmaceuticals Inc. subsidiary and the university partnered to conduct an open-label, dose-escalation, U.S. Phase I/II trial to evaluate the biotech's AIR001 to treat...
21:09 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

AIR001: Ph II INABLE-TRAINING started

Mast began the double-blind, placebo-controlled, U.S. Phase II INABLE-TRAINING trial to evaluate 80 mg inhaled AIR001 thrice daily for 12 weeks in about 68 patients undergoing exercise training as part of standard cardiac rehab. Mast...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Mast Therapeutics cardiovascular, hematology news

Mast said it will discontinue clinical development of vepoloxamer ( MST-188 ) and focus on developing aironite ( AIR001 ) to treat heart failure with preserved ejection fraction (HFpEF). Last month, Mast reported that vepoloxamer...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Aironite: Phase II started

Mast said Duke Clinical Research Institute began the double-blind, placebo-controlled, crossover, U.S. Phase II INDIE-HFpEF trial to evaluate thrice-daily AIR001 in about 100 heart failure patients ages >40 with preserved ejection fraction. Mast Therapeutics Inc....
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

Aironite: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 30 heart failure patients with preserved ejection fraction showed that 90 mg inhaled AIR001 met the primary endpoint of improving pulmonary capillary wedge pressure at...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Aironite: Phase IIa started

Mast said the Mayo Clinic began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 90 mg inhaled AIR001 in about 30 patients. Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif.   Product: Aironite ( AIR001...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Aironite: Phase IIa amended

Mast said the University of Pittsburgh amended an open-label, U.S. Phase IIa trial of 45 and 90 mg inhaled AIR001 to include 20 patients with WHO group II pulmonary hypertension (PH) and PH associated with...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

Aironite: Phase II data

Top-line data from the open-label, international Phase II AIR001-CS05 trial in 29 patients with PAH showed that all doses of AIR001 improved median PVR, the primary endpoint, and 6MWD, a secondary endpoint. Patients received 46...